Mount Yale Investment Advisors LLC Has $2.37 Million Stock Position in STERIS plc (NYSE:STE)

Mount Yale Investment Advisors LLC decreased its position in shares of STERIS plc (NYSE:STE) by 16.5% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 10,774 shares of the medical equipment provider’s stock after selling 2,131 shares during the period. Mount Yale Investment Advisors LLC’s holdings in STERIS were worth $2,365,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in STERIS by 0.5% during the fourth quarter. Vanguard Group Inc. now owns 11,864,606 shares of the medical equipment provider’s stock valued at $2,608,434,000 after purchasing an additional 53,526 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its position in STERIS by 13.7% during the second quarter. Massachusetts Financial Services Co. MA now owns 6,442,805 shares of the medical equipment provider’s stock valued at $1,414,453,000 after purchasing an additional 778,613 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in STERIS by 7.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,738,630 shares of the medical equipment provider’s stock valued at $390,880,000 after purchasing an additional 120,616 shares during the last quarter. Sustainable Growth Advisers LP boosted its position in STERIS by 23.5% during the first quarter. Sustainable Growth Advisers LP now owns 1,485,578 shares of the medical equipment provider’s stock valued at $333,988,000 after purchasing an additional 282,387 shares during the last quarter. Finally, Impax Asset Management Group plc boosted its position in STERIS by 29.7% during the second quarter. Impax Asset Management Group plc now owns 1,150,517 shares of the medical equipment provider’s stock valued at $251,663,000 after purchasing an additional 263,383 shares during the last quarter. Institutional investors and hedge funds own 94.69% of the company’s stock.

Insider Activity at STERIS

In related news, Director Christopher S. Holland sold 473 shares of the business’s stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $239.68, for a total transaction of $113,368.64. Following the transaction, the director now directly owns 582 shares in the company, valued at $139,493.76. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CFO Michael J. Tokich sold 23,332 shares of the business’s stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $247.00, for a total transaction of $5,763,004.00. Following the transaction, the chief financial officer now directly owns 42,930 shares in the company, valued at $10,603,710. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Christopher S. Holland sold 473 shares of STERIS stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $239.68, for a total value of $113,368.64. Following the sale, the director now directly owns 582 shares in the company, valued at $139,493.76. The disclosure for this sale can be found here. Corporate insiders own 1.14% of the company’s stock.

Wall Street Analysts Forecast Growth

STE has been the topic of several recent research reports. KeyCorp raised their target price on STERIS from $255.00 to $265.00 and gave the company an “overweight” rating in a report on Tuesday, September 3rd. StockNews.com upgraded STERIS from a “hold” rating to a “buy” rating in a report on Tuesday, August 13th. Stephens restated an “overweight” rating and set a $260.00 target price on shares of STERIS in a report on Wednesday, August 7th. JMP Securities restated a “market outperform” rating and set a $265.00 target price on shares of STERIS in a report on Wednesday, August 7th. Finally, Needham & Company LLC restated a “hold” rating on shares of STERIS in a report on Thursday, August 8th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, STERIS has a consensus rating of “Moderate Buy” and a consensus target price of $246.00.

STERIS Trading Down 1.0 %

STERIS stock opened at $236.98 on Friday. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.49 and a current ratio of 2.33. The business’s 50-day simple moving average is $236.26 and its 200-day simple moving average is $225.53. The firm has a market capitalization of $23.43 billion, a PE ratio of 62.04 and a beta of 0.83. STERIS plc has a 52 week low of $195.47 and a 52 week high of $248.24.

STERIS (NYSE:STE) last posted its quarterly earnings data on Tuesday, August 6th. The medical equipment provider reported $2.14 EPS for the quarter, topping analysts’ consensus estimates of $1.98 by $0.16. The business had revenue of $1.28 billion for the quarter, compared to analyst estimates of $1.27 billion. STERIS had a return on equity of 13.85% and a net margin of 7.36%. The firm’s revenue for the quarter was down .4% on a year-over-year basis. During the same period in the previous year, the company posted $2.00 earnings per share. Equities research analysts forecast that STERIS plc will post 9.05 earnings per share for the current year.

STERIS Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, September 20th. Investors of record on Thursday, September 5th were paid a dividend of $0.57 per share. This represents a $2.28 annualized dividend and a yield of 0.96%. This is a positive change from STERIS’s previous quarterly dividend of $0.52. The ex-dividend date was Thursday, September 5th. STERIS’s payout ratio is currently 59.69%.

STERIS Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.